🟢 Outlook Therapeutics is trading 8.5% up today on positioning ahead of FDA decision for Lytenava

Outlook Therapeutics is trading 8.5% up at $1.74 as traders continue to position ahead of the upcoming FDA decision on its eye drug Lytenava.

• The upward move follows last month’s FDA acceptance of the resubmitted Biologics License Application (BLA) and confirmation that no new clinical trials are required.
• The stock is exhibiting strong stock-specific momentum despite broader biotech sector weakness, driven by retail and analyst focus on the July 29, 2026, PDUFA-style decision date.